Acute Porphyria Drug Database

L01BB06 - Clofarabine
Not porphyrinogenic
NP

Rationale
Non-CYP metabolism. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
Clofarabine is a purine nucleoside antimetabolite, phosphorylated in the target cell to cytotoxic clorarabine triphosphate.
Therapeutic characteristics
Clofarabine is used in the treatment of children with therapy resistant acute lymphatic leukaemia, where no other treatment is expected to be effective. Administered as an intravenous infusion. Common adverse reactions of clofarabine that can be confused with an acute porphyric attack are nausea, vomiting, diarrhoea, and abdominal pain as well as agitation, irritability, tachycardia, ascending neuropathy and paraesthesias. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Metabolism and pharmacokinetics
Eliminated via a combination of renal and non-renal excretion. 60 % of the dose is excreted unchanged in urine within 24 hours. Non-renal elimination is not elucidated but does not include CYP-metabolism. No data supporting capacity for CYP-induction or inhibition. Interaction with drugs that induce or inhibit cytochrome P-450 (CYP) isoenzymes has not been registered and is not expected.
IPNet drug reports
No.

References

  1. Drug reference publications
  2. McEvoy GK, editor. Clofarabine. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (02.12.09). #3331
  3. Sweetman SC, editor. Martindale: The complete drug reference. Clofarabine. Pharmaceutical Press 2009. #3333
  4. Summary of Product Characteristics
  5. Norwegian medicines agency. Summary of Product Characteristics (SPC). Evoltra. #3332

Similar drugs
Explore alternative drugs in similar therapeutic classes L01B / L01BB or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙